Overcoming Resistance to DNA-Targeted Agents by Epigenetic Activation of Schlafen 11 (SLFN11) Expression with Class I Histone Deacetylase Inhibitors

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Clinical Cancer Research

• Publication date

  2018-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-17-0443PMID 29391350PMCID PMC5899656
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Integrated pan-cancer gene expression and drug sensitivity analysis reveals SLFN11 mRNA as a solid tumor biomarker predictive of sensitivity to DNA-damaging chemotherapy

  2019cited by this paper
• Epigenetic targeting of DNA repair in lung cancer

  2019cited by this paper
• SLFN11 Blocks Stressed Replication Forks Independently of ATR.

  2018cited by this paper
• Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis.

  2017influential reference
• DNA-Targeted Precision Medicine; Have we Been Caught Sleeping?

  2017cited by this paper
• The NCI-60 Methylome and Its Integration into CellMiner.

  2017cited by this paper
• PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer

  2016cited by this paper
• Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA Expression.

  2016cited by this paper
• Feedback Activation of Leukemia Inhibitory Factor Receptor Limits Response to Histone Deacetylase Inhibitors in Breast Cancer.

  2016cited by this paper
• Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition

  2016cited by this paper
• Correlating chemical sensitivity and basal gene expression reveals mechanism of action

  2015cited by this paper
• Episensitization: Defying Time’s Arrow

  2015cited by this paper
• SLFN11 inhibits checkpoint maintenance and homologous recombination repair

  2015cited by this paper
• High SLFN11 expression predicts better survival for patients with KRAS exon 2 wild type colorectal cancer after treated with adjuvant oxaliplatin-based treatment

  2015cited by this paper
• SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma

  2015cited by this paper
• Romidepsin in peripheral and cutaneous T‐cell lymphoma: mechanistic implications from clinical and correlative data

  2015cited by this paper
• Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs

  2015cited by this paper
• Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), in Ewing's Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High SLFN11 Expression

  2015cited by this paper
• High Resolution Copy Number Variation Data in the NCI-60 Cancer Cell Lines from Whole Genome Microarrays Accessible through CellMiner

  2014cited by this paper
• Schlafen-11 sensitizes colorectal carcinoma cells to irinotecan

  2014cited by this paper
• New and emerging HDAC inhibitors for cancer treatment.

  2014cited by this paper
• Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders

  2014cited by this paper
• The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.

  2013cited by this paper
• Multiplex Genome Engineering Using CRISPR/Cas Systems

  2013cited by this paper
• The Schlafen Family of Proteins and Their Regulation by Interferons

  2013influential reference
• MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor.

  2013cited by this paper
• Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents

  2012cited by this paper
• The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity

  2012cited by this paper
• Codon-usage-based inhibition of HIV protein synthesis by human schlafen 11

  2012cited by this paper
• DNA topoisomerases and their poisoning by anticancer and antibacterial drugs.

  2010cited by this paper
• Histone deacetylase inhibitors and genomic instability.

  2009cited by this paper
• NCBI GEO: archive for high-throughput functional genomic data

  2008cited by this paper
• Attenuated DNA Damage Repair by Trichostatin A through BRCA1 Suppression

  2007cited by this paper
• HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination

  2007cited by this paper

• Mechanisms of Gemcitabine Resistance in Pancreatic Cancer

  2026cites this paper
• Diverse Mechanisms of Smarcb1 Inactivation and Genome Maintenance Defects in Ultra-Rare Malignant Rhabdoid Tumors

  2026cites this paper
• From predictive biomarker to therapeutic target: the dual role of SLFN11 in chemotherapy sensitivity

  2025cites this paper
• MMR deficiency is frequent in colorectal carcinomas with diffuse SLFN11 immunostaining: clinicopathologic and molecular study of 31 cases identified among 3,300 tumors

  2025cites this paper
• The translational potential of epigenetic modulatory bioactive phytochemicals as adjuvant therapy against cancer.

  2025cites this paper
• SLFN11 puts the brakes on Alternative lengthening of telomeres

  2025cites this paper
• Schlafen 11 as a predictive biomarker and therapeutic target in cancer: From mechanisms to clinical application.

  2025cites this paper
• Epigenetic and Post-Translational Regulation of Schlafen Family Expression and Their Differential Methods of Regulating Proteins

  2025cites this paper
• Co-expression of CD30 and SLFN11 serves as a dual biomarker for the treatment of cutaneous T-cell lymphoma

  2025cites this paper
• Pharmacogenomic Characterization of a Large Cohort of Patient-Derived Cell Lines Identifies Therapeutic Strategies for Pleural Mesothelioma.

  2025cites this paper
• SLFN11, far from being limited to responding to cancer DNA damage

  2025cites this paper
• Clinical insight on the pathway of SLFN11 as emergent biomarker in SCLC.

  2025cites this paper
• SLFN11: a pan-cancer biomarker for DNA-targeted drugs sensitivity and therapeutic strategy guidance

  2025cites this paper
• SLFN11 Enhances Cisplatin Sensitivity in Pediatric Cancer via Activation of Stress-Response and Suppression of Survival Pathways

  2025cites this paper
• SLFN11 promotes clear cell renal cell carcinoma progression via the PI3K/AKT signaling pathway

  2024cites this paper
• SLFN12 Expression Significantly Effects the Response to Chemotherapy Drugs in Triple-Negative Breast Cancer

  2024cites this paper
• Research progress of the SLFN family in malignant tumors

  2024cites this paper
• Strategies to Target Chemoradiotherapy Resistance in Small Cell Lung Cancer

  2024cites this paper
• Immunohistochemical Evaluation of Schlafen 11 (SLFN11) Expression in Cancer in the Search of Biomarker-Informed Treatment Targets

  2024cites this paper
• SLFN11 and ATR as targets for overcoming cisplatin resistance in ovarian cancer cells.

  2024cites this paper
• Methylation synthetic lethality: Exploiting selective drug targets for cancer therapy.

  2024cites this paper
• The emerging role of Schlafen-11 (SLFN11) in predicting response to anticancer treatments: Focus on small cell lung cancer.

  2024cites this paper
• DNA damage response defects in hematologic malignancies: mechanistic insights and therapeutic strategies.

  2024cites this paper
• The expression of SLFN11 is related to the sensitivity of bladder cancer cells to DNA damage agents

  2024cites this paper
• Modulation of SLFN11 induces changes in DNA Damage response in breast cancer

  2023cites this paper
• Actionable Driver Events in Small Cell Lung Cancer

  2023cites this paper
• Targeting YB-1 via entinostat enhances cisplatin sensitivity of pleural mesothelioma in vitro and in vivo.

  2023cites this paper
• Entinostat Enhances the Efficacy of Chemotherapy in Small Cell Lung Cancer Through S-phase Arrest and Decreased Base Excision Repair

  2023cites this paper
• Targeted Therapy for EWS-FLI1 in Ewing Sarcoma

  2023cites this paper
• Novel therapeutic strategies for recurrent SCLC.

  2023cites this paper
• Can Schlafen 11 Help to Stratify Ovarian Cancer Patients Treated with DNA-Damaging Agents?

  2022cites this paper
• Pharmacologic Induction of BRCAness in BRCA-Proficient Cancers: Expanding PARP Inhibitor Use

  2022cites this paper
• Structural, molecular, and functional insights into Schlafen proteins

  2022cites this paper
• Novel therapeutic combinations with PARP inhibitors for small cell lung cancer: A bench-to-bedside review.

  2022cites this paper
• SLFN11 Negatively Regulates Noncanonical NFκB Signaling to Promote Glioblastoma Progression

  2022influential citation
• Combined inhibition of PARP and EZH2 for cancer treatment: Current status, opportunities, and challenges

  2022cites this paper
• Integrative epigenomic analyses of small cell lung cancer cells demonstrates the clinical translational relevance of gene body methylation

  2022cites this paper
• Epigenetic upregulation of Schlafen11 renders WNT- and SHH- activated medulloblastomas sensitive to cisplatin.

  2022cites this paper
• A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma

  2022influential citation
• The molecular mechanism of METTL3 promoting the malignant progression of lung cancer

  2022cites this paper
• FK228 potentiates topotecan activity against small cell lung cancer cells via induction of SLFN11

  2021cites this paper
• Epigenetic suppression of SLFN11 in germinal center B-cells during B-cell development

  2021cites this paper
• SLFN11 promotes CDT1 degradation by CUL4 in response to replicative DNA damage, while its absence leads to synthetic lethality with ATR/CHK1 inhibitors

  2021influential citation
• PARP Inhibitors in Small-Cell Lung Cancer: Rational Combinations to Improve Responses

  2021cites this paper
• Resistance to Pyrrolobenzodiazepine Dimers Is Associated with SLFN11 Downregulation and Can Be Reversed through Inhibition of ATR

  2021cites this paper
• Schlafen 11 predicts response to platinum-based chemotherapy in gastric cancers

  2021cites this paper
• Functions of Thrombospondin-1 in the Tumor Microenvironment

  2021cites this paper
• A wake-up call for cancer DNA damage: the role of Schlafen 11 (SLFN11) across multiple cancers

  2021cites this paper
• Precision Oncology with Drugs Targeting the Replication Stress, ATR, and Schlafen 11

  2021cites this paper
• Schlafens: Emerging Proteins in Cancer Cell Biology

  2021cites this paper
• Schlafen 11 expression in human acute leukemia cells with gain-of-function mutations in the interferon-JAK signaling pathway

  2021cites this paper
• Class 1 Histone Deacetylases and Ataxia-Telangiectasia Mutated Kinase Control the Survival of Murine Pancreatic Cancer Cells upon dNTP Depletion

  2021cites this paper
• Prognostic impact of Schlafen 11 in bladder cancer patients treated with platinum‐based chemotherapy

  2021cites this paper
• DNA Methylation Analysis in Plasma Cell-Free DNA and Paired CTCs of NSCLC Patients before and after Osimertinib Treatment

  2021cites this paper
• AGGRESSIVE LYMPHOMAS: WHAT NOVEL APPROACHES ARE READY FOR PRIME TIME? Can we use epigenetics to prime chemoresistant lymphomas?

  2020cites this paper
• BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers

  2020cites this paper
• PARP and PARG inhibitors in cancer treatment.

  2020cites this paper
• Eltrombopag inhibits the proliferation of Ewing sarcoma cells via iron chelation and impaired DNA replication

  2020cites this paper
• Can we use epigenetics to prime chemoresistant lymphomas?

  2020cites this paper
• Epigenetic suppression of SLFN11 in germinal center B cells in the process of the dynamic expression change during B-cell development

  2020cites this paper
• Epigenome-wide DNA methylation analysis of small cell lung cancer cell lines suggests potential chemotherapy targets

  2020cites this paper
• Understanding the Mechanisms by Which Epigenetic Modifiers Avert Therapy Resistance in Cancer

  2020cites this paper
• Advances in Small-Cell Lung Cancer (SCLC) Translational Research.

  2020cites this paper
• The first evidence for SLFN11 expression as an independent prognostic factor for patients with esophageal cancer after chemoradiotherapy

  2020cites this paper
• Immunohistochemical analysis of SLFN11 expression uncovers potential non-responders to DNA-damaging agents overlooked by tissue RNA-seq

  2020cites this paper
• SLFN11 informs on standard of care and novel treatments in a wide range of cancer models

  2020cites this paper
• Chidamide increases the sensitivity of Non-small Cell Lung Cancer to Crizotinib by decreasing c-MET mRNA methylation

  2020cites this paper
• Chromatin Remodeling and Immediate Early Gene Activation by SLFN11 in Response to Replication Stress.

  2020cites this paper
• Schlafen-11 expression is associated with immune signatures and basal-like phenotype in breast cancer

  2019cites this paper
• SLFN11 is a general target for enhancing the sensitivity of cancer to chemotherapy (DNA-damaging agents)

  2019influential citation
• Assessment and relevance of the putative DNA/RNA helicase Schlafen-11 in ovarian and breast cancer

  2019cites this paper
• Integrated pan-cancer gene expression and drug sensitivity analysis reveals SLFN11 mRNA as a solid tumor biomarker predictive of sensitivity to DNA-damaging chemotherapy

  2019cites this paper
• Epigenetic targeting of DNA repair in lung cancer

  2019cites this paper
• PDE3A inhibitor anagrelide activates death signaling pathway genes and synergizes with cell death-inducing cytokines to selectively inhibit cancer cell growth.

  2019cites this paper
• Interferon signaling in cancer. Non-canonical pathways and control of intracellular immune checkpoints.

  2019cites this paper
• Identification of Schlafen-11 as a Target of CD47 Signaling That Regulates Sensitivity to Ionizing Radiation and Topoisomerase Inhibitors

  2019cites this paper
• Chemoresistance in Pancreatic Cancer

  2019influential citation
• The Indenoisoquinoline TOP1 Inhibitors Selectively Target Homologous Recombination-Deficient and Schlafen 11-Positive Cancer Cells and Synergize with Olaparib

  2019cites this paper
• Pharmacoepigenetic Processors: Epigenetic Drugs, Drug Resistance, Toxicoepigenetics, and Nutriepigenetics

  2019cites this paper
• Impact of Tumour Hypoxia on Evofosfamide Sensitivity in Head and Neck Squamous Cell Carcinoma Patient-Derived Xenograft Models

  2019cites this paper
• Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies.

  2019cites this paper
• Nucleobase and Nucleoside Analogues: Resistance and Re-Sensitisation at the Level of Pharmacokinetics, Pharmacodynamics and Metabolism

  2018cites this paper
• The schlafen core domain: from structure to function

  2018cites this paper
• Novel Fluoroindenoisoquinoline Non-Camptothecin Topoisomerase I Inhibitors

  2018cites this paper